Industry seeks trust and louder voice in HTA evolution, says EFPIA
This article was originally published in Scrip
Executive Summary
The pharmaceutical industry has so far had only narrow input into a European pilot that saw numerous health technology assessment (HTA) bodies work together to assess the relative effectiveness of GlaxoSmithKline's Votrient. With greater collaboration on relative effectiveness edging forward, industry should have a bigger say on how HTA evolves, says EFPIA, the European Federation of Pharmaceutical Industry Associations.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.